Treatment and survival of children with ph+ acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks back at the diagnosis, treatment, and survival of children with a specific type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to understand how well standard treatments, including targeted therapy, work in these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient was between 1 month and 18 years old when diagnosed with leukemia.
- The leukemia tested positive for a specific genetic change called the BCR-ABL fusion gene.
- The patient received standard targeted therapy (like imatinib or dasatinib) as part of their treatment.
- The patient had regular blood or bone marrow tests during treatment to check for very small amounts of remaining leukemia cells (called minimal residual disease or MRD).
- The patient does not have mixed-lineage leukemia or another cancer at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a new treatment plan for children with very high-risk acute lymphoblastic leukemia. It aims to improve outcomes for patients whose leukemia has specific genetic markers or has not responded well to initial treatment.
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see how well the treatment works and to manage the disease, with some patients also receiving a stem cell transplant.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hear when a new Acute Lymphoblastic Leukemia, Pediatric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.